Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J W van Kampen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Netherlands Journal of Medicine|September 25, 2007
Thorium dioxide-related haemangiosarcoma of the liverR J W van Kampen, F L G Erdkamp, F P J Peters
Nederlands Tijdschrift Voor Geneeskunde|July 11, 2006
[Serious intoxication after inhaling methanol]R J W van Kampen, M M E Krekels, H J Derijks, et al.
Journal of Thrombosis and Haemostasis : JTH|March 11, 2004
Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristicsK Vanschoonbeek, M A H Feijge, R J W Van Kampen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2017
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer ConsortiumR J W van Kampen, B L T Ramaekers, D J A Lobbezoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer ConsortiumD J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
British Journal of Cancer|April 17, 2015
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trialM R Seefat, C A M Stege, B I Lissenberg-Witte, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Netherlands Journal of Medicine|September 25, 2007
Thorium dioxide-related haemangiosarcoma of the liverR J W van Kampen, F L G Erdkamp, F P J Peters
Nederlands Tijdschrift Voor Geneeskunde|July 11, 2006
[Serious intoxication after inhaling methanol]R J W van Kampen, M M E Krekels, H J Derijks, et al.
Journal of Thrombosis and Haemostasis : JTH|March 11, 2004
Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristicsK Vanschoonbeek, M A H Feijge, R J W Van Kampen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2017
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer ConsortiumR J W van Kampen, B L T Ramaekers, D J A Lobbezoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer ConsortiumD J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
British Journal of Cancer|April 17, 2015
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trialM R Seefat, C A M Stege, B I Lissenberg-Witte, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 1